# A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies

> **NCT07011186** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 138 (estimated)

## Conditions studied

- Myeloid Malignancy

## Interventions

- **DRUG:** TQB3909 Tablets + Azacitidine

## Key facts

- **NCT ID:** NCT07011186
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-17
- **Primary completion:** 2025-10
- **Final completion:** 2026-10
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07011186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07011186, "A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07011186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*